PFE - Pfizer Inc.

NYSE - NYSE Delayed Price. Currency in USD
36.46
-0.18 (-0.49%)
At close: 4:00PM EST

36.58 +0.12 (0.33%)
After hours: 7:58PM EST

Stock chart is not supported by your current browser
Previous Close36.64
Open36.73
Bid0.00 x 0
Ask0.00 x 0
Day's Range36.34 - 36.89
52 Week Range30.90 - 36.89
Volume14,786,943
Avg. Volume15,931,475
Market Cap217.327B
Beta1.07
PE Ratio (TTM)22.52
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.28 (3.50%)
Ex-Dividend Date2017-11-09
1y Target EstN/A
Trade prices are not sourced from all markets
  • Reuters2 hours ago

    Pfizer's Xeljanz gets FDA nod as joint disease treatment

    U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease. Xeljanz was approved as a 5-mg dose taken twice daily and as an extended-release 11-mg dose taken once daily as a drug for patients with active psoriatic arthritis who have not responded to other treatments. Psoriatic arthritis, a form of arthritis that affects some people who have skin disease psoriasis, is characterized by symptoms such as joint pain, stiffness and swelling.

  • Barrons.com6 hours ago

    Valeant: Down It Goes!

    Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.

  • Forbes7 hours ago

    Pfizer's Bet On Oncology

    Pfizer’s Oncology segment accounts for less than 20% of the company’s value, according to our estimates. For many other major pharma companies, their oncology portfolios are larger contributors to their top lines, and Pfizer has been looking to capitalize on opportunities in the space.

  • Pfizer's Second Biosimilar of Remicade Receives FDA Approval
    Zacks7 hours ago

    Pfizer's Second Biosimilar of Remicade Receives FDA Approval

    The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.

  • TheStreet.com8 hours ago

    Teva Options Jump to Record Amid New CEO's Latest Bid for Turnaround

    Teva options now total more than Pfizer and Merck combined.

  • 10 Biggest Antidepressant Drug Companies In 2017
    Insider Monkey12 hours ago

    10 Biggest Antidepressant Drug Companies In 2017

    The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]

  • Reutersyesterday

    Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

    The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer's Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn's disease and skin disorder plaque psoriasis, the drugmaker said. With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc's Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea's Samsung Bioepis Co Ltd.

  • This Biotech Stock Rocketed On Human Trials For New Cancer Drug
    Investor's Business Dailyyesterday

    This Biotech Stock Rocketed On Human Trials For New Cancer Drug

    Cellectis popped early Wednesday after it and Dow's Pfizer presented strong data for first in-human trials of a cancer therapy.

  • 24/7 Wall St.yesterday

    Why Cellectis Is Winning Big With Its Pfizer Partnership

    Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.

  • 5 Biotech Buyout Candidates for 2018
    Motley Fool2 days ago

    5 Biotech Buyout Candidates for 2018

    The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.

  • Why 2017 Was a Year to Forget for Pfizer Inc.
    Motley Fool2 days ago

    Why 2017 Was a Year to Forget for Pfizer Inc.

    Pfizer's 2017 wasn't horrible. Just ho-hum.

  • Market Realist2 days ago

    What Analysts Recommend for Eli Lilly in December 2017

    In October 2017, Eli Lilly (LLY) and CureVac announced a global collaboration for immuneoncology research.

  • Spark Therapeutics Stock Plunges on Hemophilia Therapy Data
    Zacks2 days ago

    Spark Therapeutics Stock Plunges on Hemophilia Therapy Data

    Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.

  • 3 Dividend Stocks to Buy on Sale
    Motley Fool3 days ago

    3 Dividend Stocks to Buy on Sale

    It's hard to go wrong with high dividend yields, low earnings multiples, and solid long-term business prospects.

  • 3 Dividend Stocks Perfect for Retirees
    Motley Fool3 days ago

    3 Dividend Stocks Perfect for Retirees

    Step right up and collect your income!

  • Forbes3 days ago

    Roche's Fight With Pfizer May Be Just The Beginning

    Roche recently sued Pfizer to block the latter’s biosimilar (generic version) for Herceptin- a cancer biologic that earned $2.5 billion in sales in the U.S. for Roche in 2016. The fight is unlikely to stop there for Roche, as it has a lot more at stake.

  • TheStreet.com3 days ago

    Teva Stock Rises After Announcing Launch of Generic Viagra Competitor

    Viagra has annual sales of about $1.4 billion.

  • Barrons.com3 days ago

    [$$] Spark Therapeutics Selloff Looks Overdone

    Spark Therapeutics shares have plunged today, falling $27, or 37%, to $44.03 after the gene-therapy company released disappointing results for its treatment for hemophilia A at the American Society of Hematology’s annual meeting in Atlanta. The data on four patients in a phase 1/2 clinical trial showed some variability in the expression of Factor VIII, the clotting protein either missing or existing at very low levels in hemophilia A patients. It appears that Spark (ONCE) has lost the lead in developing a hemophilia A treatment to BioMarin Pharmaceutical (BMRN), a much larger biotechnology company that reported consistent levels of Factor VIII expression at the ASH conference in a phase 1/2 trial for its gene-therapy treatment.

  • 3 Top Stocks With High Dividend Yields
    Motley Fool3 days ago

    3 Top Stocks With High Dividend Yields

    You don't have to sacrifice growth when looking to bolster income: Some stocks offer both.

  • Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study
    Zacks3 days ago

    Pfizer's (PFE) Talazoparib Emerges Superior in EMBRACA Study

    Pfizer's (PFE) breast cancer candidate demonstrates superiority over chemotherapy in phase III study in previously treated breast cancer patients.

  • Sex, Drugs, and Teva Pharmaceutical Industries (TEVA)
    SmarterAnalyst3 days ago

    Sex, Drugs, and Teva Pharmaceutical Industries (TEVA)

    Today, the generic drug giant announced the exclusive launch of its generic Viagra (sildenafil citrate) tablets in the U.S. Viagra (generic name sildenafil) is a drug used in the treatment of erectile dysfunction, also known as impotence. Introduced by Pfizer Inc. in March 1998, Viagra has generated about $1.4 billion in the U.S., according to IMS data as of August 2017.

  • TheStreet.com4 days ago

    Blueprint Medicines and Bluebird Bio Soar on ASH Announcements -- Biotech Movers

    Blueprint unveiled new data from its ongoing Phase 1 study of avapritinib in advanced systemic mastocytosis at the 59th American Society of Hematology Annual Meeting.

  • 3 High-Yield Dividend Stocks to Buy in 2018
    Motley Fool4 days ago

    3 High-Yield Dividend Stocks to Buy in 2018

    These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.

  • MarketWatch4 days ago

    Teva's stock gains after exclusive launch of generic Viagra

    Shares of Teva Pharmaceutical Industries Ltd. rose 0.4% in morning trade Monday, after the drug maker announced the exclusive launch of its generic Viagra tablets in the U.S. The company said it will offer ...

  • Merck lagging this year, but charts show it's poised for ...
    CNBC Videos3 days ago

    Merck lagging this year, but charts show it's poised for ...

    Carter Worth, Cornerstone Macro, discusses one lagging stock that could make a comeback.